BioPharma Dive1d
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
AstraZeneca PLC ADR rises Tuesday, outperforms market
AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.
AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
NDAQ:AZN) AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm ...
BioSpace1d
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
AstraZeneca overhauls management of its China division, FT reports
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
AstraZeneca’s Strong Growth Forecasts and Strategic Position Justify Buy Rating Despite Market Concerns
Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...
BioSpace1d
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
News Medical on MSN6d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina Maker
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
AstraZeneca rises Tuesday, outperforms market
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.